Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Published:2021-05-03 Issue:9 Volume:64 Page:6037-6058
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mammoliti Oscar¹^ORCID,Palisse Adeline¹,Joannesse Caroline¹,El Bkassiny Sandy¹,Allart Brigitte¹,Jaunet Alex¹,Menet Christel¹,Coornaert Beatrice¹,Sonck Kathleen¹,Duys Inge¹,Clément-Lacroix Philippe²,Oste Line¹,Borgonovi Monica²,Wakselman Emanuelle²,Christophe Thierry¹,Houvenaghel Nicolas¹,Jans Mia¹,Heckmann Bertrand²,Sanière Laurent²,Brys Reginald¹

Affiliation:

1. Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

2. Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00138

Reference63 articles.

1. An update on sphingosine-1-phosphate and other sphingolipid mediators

2. Extracellular and Intracellular Actions of Sphingosine-1-Phosphate